Yun MR - Search Results

1

Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC.

Lee EJ, Oh SY, Lee YW, Kim JY, Kim MJ, Kim TH, Lee JB, Hong MH, Lim SM, Baum A, Woelflingseder L, Engelhardt H, Petronczki M, Solca F, Yun MR, Cho BC. Lee EJ, et al. Among authors: yun mr. Clin Cancer Res. 2024 Apr 15;30(8):1582-1594. doi: 10.1158/1078-0432.CCR-23-2951. Clin Cancer Res. 2024. PMID: 38330145

2

YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer.

Yun J, Hong MH, Kim SY, Park CW, Kim S, Yun MR, Kang HN, Pyo KH, Lee SS, Koh JS, Song HJ, Kim DK, Lee YS, Oh SW, Choi S, Kim HR, Cho BC. Yun J, et al. Among authors: yun mr. Clin Cancer Res. 2019 Apr 15;25(8):2575-2587. doi: 10.1158/1078-0432.CCR-18-2906. Epub 2019 Jan 22. Clin Cancer Res. 2019. PMID: 30670498

3

Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer.

Yun MR, Kim DH, Kim SY, Joo HS, Lee YW, Choi HM, Park CW, Heo SG, Kang HN, Lee SS, Schoenfeld AJ, Drilon A, Kang SG, Shim HS, Hong MH, Cui JJ, Kim HR, Cho BC. Yun MR, et al. Clin Cancer Res. 2020 Jul 1;26(13):3287-3295. doi: 10.1158/1078-0432.CCR-19-2777. Epub 2020 Apr 8. Clin Cancer Res. 2020. PMID: 32269053 Free PMC article.

4

Preclinical Study of a Biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC.

Oh SY, Lee YW, Lee EJ, Kim JH, Park Y, Heo SG, Yu MR, Hong MH, DaSilva J, Daly C, Cho BC, Lim SM, Yun MR. Oh SY, et al. Among authors: yun mr. Clin Cancer Res. 2023 Jan 4;29(1):221-232. doi: 10.1158/1078-0432.CCR-22-2180. Clin Cancer Res. 2023. PMID: 36269795

5

Glycolysis inhibition sensitizes non-small cell lung cancer with T790M mutation to irreversible EGFR inhibitors via translational suppression of Mcl-1 by AMPK activation.

Kim SM, Yun MR, Hong YK, Solca F, Kim JH, Kim HJ, Cho BC. Kim SM, et al. Among authors: yun mr. Mol Cancer Ther. 2013 Oct;12(10):2145-56. doi: 10.1158/1535-7163.MCT-12-1188. Epub 2013 Jul 24. Mol Cancer Ther. 2013. PMID: 23883584

6

EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines.

Kim SM, Kim H, Jang KW, Kim MH, Sohn J, Yun MR, Kang HN, Kang CW, Kim HR, Lim SM, Moon YW, Kim JH, Paik S, Cho BC. Kim SM, et al. Among authors: yun mr. Mol Cancer Ther. 2016 Jul;15(7):1627-36. doi: 10.1158/1535-7163.MCT-15-0375. Epub 2016 May 11. Mol Cancer Ther. 2016. PMID: 27196768 Retracted.

7

Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors.

Yun MR, Lim SM, Kim SK, Choi HM, Pyo KH, Kim SK, Lee JM, Lee YW, Choi JW, Kim HR, Hong MH, Haam K, Huh N, Kim JH, Kim YS, Shim HS, Soo RA, Shih JY, Yang JC, Kim M, Cho BC. Yun MR, et al. Cancer Res. 2018 Jun 15;78(12):3350-3362. doi: 10.1158/0008-5472.CAN-17-3146. Epub 2018 Apr 18. Cancer Res. 2018. PMID: 29669761

8

Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC.

Yun J, Lee SH, Kim SY, Jeong SY, Kim JH, Pyo KH, Park CW, Heo SG, Yun MR, Lim S, Lim SM, Hong MH, Kim HR, Thayu M, Curtin JC, Knoblauch RE, Lorenzi MV, Roshak A, Cho BC. Yun J, et al. Among authors: yun mr. Cancer Discov. 2020 Aug;10(8):1194-1209. doi: 10.1158/2159-8290.CD-20-0116. Epub 2020 May 15. Cancer Discov. 2020. PMID: 32414908 Clinical Trial.

9

Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer.

Pyo KH, Lim SM, Park CW, Jo HN, Kim JH, Yun MR, Kim D, Xin CF, Lee W, Gheorghiu B, Hong MH, Kim HR, Shim HS, Jang M, Lee SS, Cho BC. Pyo KH, et al. Among authors: yun mr. J Immunother Cancer. 2020 Jul;8(2):e000970. doi: 10.1136/jitc-2020-000970. J Immunother Cancer. 2020. PMID: 32727812 Free PMC article.

10

Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma.

Kim SY, Kim SM, Lim S, Lee JY, Choi SJ, Yang SD, Yun MR, Kim CG, Gu SR, Park C, Park AY, Lim SM, Heo SG, Kim H, Cho BC. Kim SY, et al. Among authors: yun mr. Clin Cancer Res. 2021 Aug 1;27(15):4397-4409. doi: 10.1158/1078-0432.CCR-20-5026. Epub 2021 Jun 3. Clin Cancer Res. 2021. PMID: 34083237 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

93 results

Search Page